

Please type a plus sign (+) inside this box ☐



PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 <b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	<b>Application Number</b>	10/644,875	
	<b>Filing Date</b>	August 21, 2003	
	<b>First Named Inventor</b>	Ying-Fei WEI, et al.	
	<b>Group/Art Unit</b>	1641	
	<b>Examiner Name</b>	Marianne ALLEN	
<b>Total Number of Pages in This Submission</b>		<b>Attorney Docket Number</b>	39766-0151D2

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Version with Markings Showing Changes <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> <b>Additional Enclosure(s) (please identify below):</b> <b>16 references submitted with the PTO 1449; stamped return postcard</b>		
<table border="1"><tr><td>Remarks</td><td><b>AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER (Reference Atty. Docket No. 39766-0151D2).</b></td></tr></table>			Remarks	<b>AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER (Reference Atty. Docket No. 39766-0151D2).</b>
Remarks	<b>AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER (Reference Atty. Docket No. 39766-0151D2).</b>			

**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

Firm or Individual name	LESLIE MOOI, Reg. No. 37,047, HELLER EHRMAN WHITE & McAULIFFE LLP		
Signature			
Date	January 5, 2005	Customer Number:	25213

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop **AMENDMENT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 20231, on this date:

Express Mail Label **EL 993 687 694 US**

Typed or printed name	Sandra Puljic		
Signature		Date	January 5, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	) Examiner: Allen, Marianne
	)
Ying-Fei WEI, et al.	) Group Art Unit: 1641
	)
Application Serial No. 10/644,875	) Attorney's Docket No. 39766-0151D2
	)
Filed: August 21, 2003	) Customer No. 25213
	)
For: TRANSFORMING GROWTH	)
FACTOR ALPHA III	)
	)
	)

EXPRESS MAIL LABEL NO.: EL 993 687 694 US  
DATE MAILED: JANUARY 5, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

**MAIL STOP: AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each publication other than U.S. patents and U.S. patent application publications, and each cited pending unpublished U.S. application pursuant to 37 C.F.R. §§1.97-1.98.

References identified with an asterisk were either previously cited by or submitted to the PTO in priority application no. **09/227,853**, filed **November 4, 2003**, or **08/930,564**, filed **June 25, 2002**, or are U.S. patents or patent application publications. Copies are thus not enclosed pursuant to 37 C.F.R. § 1.98(d) and/or 1276 OG 55.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. As form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --

- ☒ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --  
☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; or

☐ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of **\$0.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39766-0151D2).**


Respectfully submitted,

Dated: January 5, 2005

By: Leslie Mooi  
Leslie Mooi (Reg. No. 37,047)

**HELLER EHRMAN WHITE & MCAULIFFE LLP**  
275 Middlefield Road  
Menlo Park, California 94025-3506  
Telephone: (650) 324-7000 / Facsimile: (650) 324-0638

SV 2091919 v1  
1/4/05 6:06 PM (39766.0151)

<b>INFORMATION DISCLOSURE STATEMENT</b>  PTO-1449			<b>ATTY. DOCKET NO.:</b> 39766-0151D2		<b>SERIAL NO.:</b> 10/644,875	
			<b>APPLICANT : Ying-Fei WEI, et al.</b>			
			<b>FILING DATE: August 21, 2003</b>		<b>GROUP: 1641</b>	
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	* US 5,182,261	1/26/1993	Tam, James P.	514/12		
	* US 5,240,912	8/31/1993	Todaro, George J.	514/12		
	* US 5,333,033 B	7/26/1994	Blackman, Robert J.	355/27		
	* US 2002/0025551 A1	2/28/2002	Holtzman, Douglas	435/69.1		
	* US 5,633,147	5/27/1997	Meissner, et al.	435/69.1		
	* US 5,831,058	11/3/1998	Fujiwara, et al.	536/23.5		
<b>FOREIGN PATENT DOCUMENTS</b>						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	* EP 0 154 434 A	1/27/1993	EP	C12N	15/16	YES <input type="checkbox"/> NO <input type="checkbox"/>
	* WO 97/25349	7/17/1997	PCT	C07K	14/495	YES <input type="checkbox"/> NO <input type="checkbox"/>
	* WO 95/14772	1/6/1995	PCT	C12N	15/11	YES <input type="checkbox"/> NO <input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	Bennett, Barbara A., et al., "HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures", Brain Research, Vol. 705, pp 168-176, 1995.					
	Davis, C. Geoffrey, et al., "The Many Faces of Epidermal Growth Factor Repeats", The New Biologist, Vol. 2, No. 5, pp 410-419, May 1990.					
	Hoogenboom, Hennie R., et al., "By-passing Immunisation Human Antibodies from Synthetic Repertoires of Germline V <sub>H</sub> Gene Segments Rearranged <i>in Vitro</i> ", J. Mol. Biol., Vol. 227, pp 381-388, 1992.					
	Horie, Masato, et al., "Identification and Characterization of TMEFF2, a Novel Survival Factor for Hippocampal and Mesencephalic Neurons", Genomics, Vol. 67, pp 146-152, 2000.					
	Itoh, Kyoko, et al., "Neuronal damage of the substantia nigra in HIV-1 infected brains", Acta Neuropathol, Vol. 99, pp 376-384, 2000.					
	Jones, Peter T., et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", Nature, Vol. 321, pp 522-525, May 29, 1986.					
	Kandel, E., et al., "The Entire Nervous System Arises From Ectoderm", Principles of Neural Science, Fourth Edition, pp 1021-1022.					
EXAMINER						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	<b>ATTY. DOCKET NO.:</b> 39766-0151D2	<b>SERIAL NO.:</b> 10/644,875
	<b>APPLICANT : Ying-Fei WEI, et al.</b>	
	<b>FILING DATE: August 21, 2003</b>	<b>GROUP: 1641</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	Marks, James D., et al., "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage", J. Mol. Biol., Vol. 222, pp 581-597, 1991.	
	Perl, Daniel, et al., "Neuropathology of Dementia", Neurologic Clinics, Vol. 4, No. 2, pp 355-368, May 1986.	
	Petito, Carol K., et al., "Hippocampal Injury and Alterations in Neuronal Chemokine Co-Receptor Expression in Patients With Aids", Journal of Neuropathology and Experimental Neurology", Vol. 60, No. 4, pp 377-385, April 2001.	
	Plata-Salamán, Carlos R., et al., "Epidermal Growth Factor and the Nervous System", Peptides, Vol. 12, pp 653-663, 1991.	
	Reichmann, Lutz, et al., "Reshaping human antibodies for therapy", Nature, Vol. 332, pp 323-327, March 24 1988.	
	Reyes M.D, Edgardo, et al., "Hippocampal Involvement Associated With Human Immunodeficiency Virus Encephalitis in Mexico", Arch. Pathol. Lab Med., Vol. 118, pp 1130-1134, November 1994.	
	Sá, M. J., et al., "AIDS does not alter the total number of neurons in the hippocampal formulation but indices cell atrophy: a stereological study", Acta Neuropathol., Vol. 99, pp 643-653, 2000.	
	Schiff, D., et al, "Bilirubin toxicity in neural cell lines N115 and NBR10A", Pediatric Research, Vol. 19, pp 908-911, 1985.	
	Verhoeven, Martine, et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", Science, Vol. 239, pp 1534-1536, February 1988.	
	* Burgess, A. W., et al., "Epidermal growth factor and transforming growth factor $\alpha$ ", British Medical Bulletin, Vol. 45, No. 2, pp 401-424, 1989.	
	* Derynck, Rik, et al. "Human Transforming Growth Factor $\alpha$ Precursor Structure and Expression in E. coli", Cell, Vol. 38, pp 287-297, August 1984.	
	* Kubly, Janis, "Antigen-Antibody Interactions", Immunology, Second Edition, pp 135-140, 1994.	
	* Gen Bank Accession No. T27101	
	* Gen Bank Accession No. Z40989	
	* Gen Bank Accession No. Z45279	
	* Gen Bank Accession No. T27100	
	* Gen Bank Accession No. R41378	
	* Gen Bank Accession No. R11739	
	* Gen Bank Accession No. R52959	
	* Gen Bank Accession No. V01875	
	* Gen Bank Accession No. T24803	
<b>EXAMINER</b>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.